Viracta Therapeutics (FRA:RYI) Additional Paid-In Capital : €260.23 Mil(As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Additional Paid-In Capital?

Viracta Therapeutics's quarterly additional paid-in capital increased from Mar. 2024 (€258.25 Mil) to Jun. 2024 (€262.09 Mil) but then stayed the same from Jun. 2024 (€262.09 Mil) to Sep. 2024 (€260.23 Mil).

Viracta Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€225.31 Mil) to Dec. 2022 (€255.54 Mil) and increased from Dec. 2022 (€255.54 Mil) to Dec. 2023 (€255.65 Mil).

Viracta Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Viracta Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Additional Paid-In Capital Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

3.88

225.31

255.54

255.65

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Additional Paid-In Capital	Get a 7-Day Free Trial														259.35	255.65	258.25	262.09	260.23

Viracta Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Viracta Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

VIRX:USA

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.